The collaboration pairs Mimulus's molecular architecture with GenScript's massive synthesis scale to liberate critical grid power for AI compute and launch the "Forever Archive" for enterprise data ...

The multi-year collaboration aims to scale molecular data storage infrastructure and unlock breakthrough cost efficiencies by ...

Strategic investment reinforces Europe as a core pillar of GenScript's global R&D and production network, following recent U.S. facility expansion. DELFT, Netherlands, March 12, 2026 /PRNewswire/ -- ...

PISCATAWAY, N.J. and LOS ANGELES, April 9, 2026 /PRNewswire/ -- GenScript Biotech Corporation, the world's leading provider of CMOS-based DNA synthesis technologies, and Mimulus Corp, the pioneer in ...

GenScript Biotech Corporation (HKEX: 1548), a global company providing life science research services and products, biologics development & manufacturing services, and industrial biotechnology ...

Jefferies analyst Cui Cui maintained a Buy rating on Genscript Biotech on April 3 and set a price target of HK$15.50. Cui covers the Healthcare sector, focusing on stocks such as Genscript Biotech, ...

PISCATAWAY, N.J., Jan. 6, 2026 /PRNewswire/ -- GenScript Biotech Corporation, a global leader in life sciences R&D and manufacturing services, is proud to announce its 5th Annual Biotech Global Forum, ...

PISCATAWAY, N.J., Jan. 28, 2026 /PRNewswire/ -- GenScript Biotech Corporation, a global leader in life science research and biotech solutions, today announced its supporting role in the experimental ...

Panel discussions brought to life important insights into how AI could change the face of biopharma drug discovery in 2026 and beyond "The conversations throughout the day reinforced that ...

The average one-year price target for Genscript Biotech (OTCPK:GNNSF) has been revised to $3.32 / share. This is an increase of 16.00% from the prior estimate of $2.86 dated April 1, 2025. The price ...